Drug intelligence / Profile preview

BI 1361849 + durvalumab

Development stage: Unknown
Lead developer: Boehringer Ingelheim
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, mRNA Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
Administration: Intradermal, Intravenous

Overview

BI 1361849 + durvalumab is a combination immunotherapy approach for non-small cell lung cancer (NSCLC). BI 1361849 is an mRNA vaccine encoding six NSCLC tumor-associated antigens (MUC1, survivin, NY-ESO-1, 5T4, MAGE-C2, and MAGE-C1), while durvalumab is an anti-PD-L1 monoclonal antibody. The combination aims to enhance anti-tumor immune responses by both priming the immune system against cancer antigens and removing immunosuppressive signals.

Other names: mRNA Vaccine + anti-PD-L1 antibody

Targets

CD274 (Programmed cell death protein 1 ligand 1)

Beyond the preview

Go deeper on BI 1361849 + durvalumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BI 1361849 + durvalumab.

Explore the full profile